The EMA's committee for medicinal products for human use (CHMP) has returned an "all clear" verdict for products containing Sanofi's insulin glargine, which had been under review for a possible increased risk of cancer.

Eight months into her new job, iPierian CEO Nancy Stagliano is outlining the company's new strategy focused on monoclonal antibodies targeting the tau protein and the complement pathway to treat neurodegenerative diseases.

Astellas is considering entering into global development and commercialisation alliances for its novel anticoagulant darexaban maleate following a regulatory setback in Japan earlier this year.

ExonHit Therapeutics is looking for financing or a partner to progress development of its lead candidate for Alzheimer's disease, EHT 0202, into Phase IIb.